Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Amparo Sanchez Gastaldo"'
Autor:
Manuel Cobo, R. López-Castro, Amparo Sanchez-Gastaldo, Alberto Ruano-Ravina, Ana Laura Ortega, Bartomeu Massuti, Anna Estival, Oscar Juan, Enric Carcereny, Gretel Benítez, Mariano Provencio, Diego Pereiro Corbacho, Juana Oramas, Ana Blasco, Joaquín Mosquera-Martínez, Marta Belver, Carlos Guirao-Rubio, María Guirado-Risueño, Joaquim Bosch-Barrera, Edel del Barco Morillo, Jose Manuel Trigo, Delvys Rodriguez-Abreu, Manuel Domine, Carlos Aguado De La Rosa, Virginia Calvo de Juan
Publikováno v:
Transl Lung Cancer Res
Translational Lung Cancer Research
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
instname
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
Scientia
r-FISABIO. Repositorio Institucional de Producción Científica
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
Translational Lung Cancer Research
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
instname
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
Scientia
r-FISABIO. Repositorio Institucional de Producción Científica
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
Càncer de pulmó; Fumar; Diferències entre sexes Cancer de pulmón; Fumar; Diferencias entre sexos Lung neoplasms; Smoking; Sex Factors Background: Lung cancer causes approximately 25% of all cancer deaths. Despite its relevance, few studies have a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10d5331ba093866069dd8c0b54f1d1fa
https://hdl.handle.net/10668/4017
https://hdl.handle.net/10668/4017
Autor:
Sonia Molina-Pinelo, Reyes Bernabé-Caro, Amparo Sanchez-Gastaldo, Miriam Alonso-García, Laura Boyero, Miguel A. Muñoz-Fuentes
Publikováno v:
Digital.CSIC. Repositorio Institucional del CSIC
instname
Transl Lung Cancer Res
instname
Transl Lung Cancer Res
[Background] Immune checkpoint inhibitors (ICIs) are currently the standard therapy in advanced non-small cell lung cancer (NSCLC); however, there is no well-established prognostic biomarker. We investigated the relationship between survival outcomes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b97e1ee77ac16ae34a6dbeab98a2853
http://hdl.handle.net/10261/266641
http://hdl.handle.net/10261/266641
Autor:
José Francisco Noguera-Uclés, Reyes Bernabé-Caro, Laura Boyero, Amparo Sanchez-Gastaldo, Sonia Molina-Pinelo, Miriam Alonso
Publikováno v:
Cancers
idUS. Depósito de Investigación de la Universidad de Sevilla
instname
idUS: Depósito de Investigación de la Universidad de Sevilla
Universidad de Sevilla (US)
Cancers, Vol 12, Iss 3729, p 3729 (2020)
idUS. Depósito de Investigación de la Universidad de Sevilla
instname
idUS: Depósito de Investigación de la Universidad de Sevilla
Universidad de Sevilla (US)
Cancers, Vol 12, Iss 3729, p 3729 (2020)
Simple Summary Immuno-oncology has redefined the treatment of lung cancer, with the ultimate goal being the reactivation of the anti-tumor immune response. This has led to the development of several therapeutic strategies focused in this direction. H
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a26d8d936c1de072426fc7591de5e9f
Autor:
José Francisco Noguera-Uclés, Miriam Alonso, Ana Salinas, Laura Boyero, Sonia Molina-Pinelo, Luis Paz-Ares, Johana Cristina Benedetti, Reyes Bernabé-Caro, Amparo Sanchez-Gastaldo, Juan Antonio Cordero Varela
Publikováno v:
Repisalud
Instituto de Salud Carlos III (ISCIII)
Cancers, Vol 12, Iss 2075, p 2075 (2020)
Cancers
Volume 12
Issue 8
Instituto de Salud Carlos III (ISCIII)
Cancers, Vol 12, Iss 2075, p 2075 (2020)
Cancers
Volume 12
Issue 8
Genomic imprinting is a process that involves one gene copy turned-off in a parent-of-origin-dependent manner. The regulation of imprinted genes is broadly dependent on promoter methylation marks, which are frequently associated with both oncogenes a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ad26025e6d7468deb87b64dcbf18afa
http://hdl.handle.net/20.500.12105/12522
http://hdl.handle.net/20.500.12105/12522
Publikováno v:
Targeted Oncology. 11:479-487
Ramucirumab (IMC-1121B, LY3009806) is a fully human G1 monoclonal antibody that specifically targets vascular endotelial growth factor receptor 2 (VEGFR-2) with a substantially greater binding affinity than that of its natural ligands. Early clinical
Autor:
Ana Nogal, Amparo Sanchez-Gastaldo, Beatriz Romero-Romero, Maria Dolores Mediano, Ricardo Melendez, Rocio Garcia-Carbonero, Sonia Molina-Pinelo, Luis Paz-Ares, José Luis López-Campos, Amancio Carnero, Maria Dolores Pastor
Publikováno v:
International Journal of Molecular Sciences, Vol 14, Iss 2, Pp 3440-3455 (2013)
International Journal of Molecular Sciences; Volume 14; Issue 2; Pages: 3440-3455
International Journal of Molecular Sciences
Digital.CSIC. Repositorio Institucional del CSIC
instname
idUS. Depósito de Investigación de la Universidad de Sevilla
International Journal of Molecular Sciences; Volume 14; Issue 2; Pages: 3440-3455
International Journal of Molecular Sciences
Digital.CSIC. Repositorio Institucional del CSIC
instname
idUS. Depósito de Investigación de la Universidad de Sevilla
Lung cancer (LC) and chronic obstructive pulmonary disease (COPD) commonly coexist in smokers, and the presence of COPD increases the risk of developing LC. Cigarette smoke causes oxidative stress and an inflammatory response in lung cells, which in
Publikováno v:
Current Clinical Pathology ISBN: 9781493920464
Kidney cancer represents around 5 % of all new cancer diagnosis in the United States, one-third of them diagnosed with locally advanced or metastatic disease. The most common form of kidney cancer arises from renal epithelium, namely, renal cell carc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f18e5f70cefe7b334f98162e2202a901
https://doi.org/10.1007/978-1-4939-2047-1_15
https://doi.org/10.1007/978-1-4939-2047-1_15
Autor:
Rafael Morales, Rosario Alfonso, B. Pérez-Valderrama, Enrique Grande, Javier Puente, Laura Carpeño, Amparo Sanchez Gastaldo, Sandra De la LLave, Joaquín Carballido, Alvaro Pinto, Ignacio Duran, Johanna Benedetti, Pablo Gajate, David Lorente, Fatima Fernandez, Miguel Angel Calleja, Joan Carles, Enrique Gonzalez-Billalabeitia
Publikováno v:
Journal of Clinical Oncology. 35:e18014-e18014
e18014 Background: With the increasing use of oral anticancer treatments understanding adherence patterns and patient’s information about therapy has become critical. Enzalutamide (ENZ) and Abiraterone acetate (AA) are orally administered drugs app
Publikováno v:
Management of Neuroendocrine Tumors of the Pancreas and Digestive Tract ISBN: 9782817804293
Neuroendocrine tumors (NETs) are a heterogeneous family of neoplasms of increasing incidence and challenging clinical management. Although generally more indolent than carcinomas, they have a widely variable clinical behavior and are on occasions ass
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::63466673d88daf59d6648c59bcedb710
https://doi.org/10.1007/978-2-8178-0430-9_13
https://doi.org/10.1007/978-2-8178-0430-9_13
Autor:
Mariano Provencio, Josefa Terrasa, Pilar Garrido, Rosario García Campelo, Francisco Aparisi, Pilar Diz, David Aguiar, Carlos García-Giron, Julia Hidalgo, Carlos Aguado, Jorge García González, Emilio Esteban, Lorenzo Gómez-Aldavarí, Teresa Moran, Oscar Juan, Luís Enrique Chara, Juan L. Marti, Rafael López Castro, Ana Laura Ortega, Elia Martínez Moreno, Juan Coves, Ana M. Sánchez Peña, Joaquim Bosch-Barrera, Amparo Sánchez Gastaldo, Natalia Fernández Núñez, Edel del Barco, Manuel Cobo, Dolores Isla, Margarita Majem, Fátima Navarro, Virginia Calvo
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-12 (2021)
Abstract Background AURA study reported 61% objective response rate and progression-free survival of 9.6 months with osimertinib in patients with EGFR/T790M+ non-small cell lung cancer. Due to lack of real-world data, we proposed this study to descri
Externí odkaz:
https://doaj.org/article/8ebc0e8ffdc84091be87e3c5b709643d